Identification of KLK10 as a therapeutic target to reverse trastuzumab resistance in breast cancer.
Trastuzumab, the first antibody widely used in anti-HER2 targeted therapy, dramatically improved the overall outcome of HER2 positive breast cancer patients. However, trastuzumab resistance emerged as a major problem in its clinical application. In order to explore mechanisms underlying trastuzumab resistance, we performed RNA-Seq to analyze the gene expression variation in trastuzumab resistant breast cancer cell line. The sequencing result was then combined with the relevant data in TCGA database to conduct a co-expression analysis. We found a series of differentially expressed genes with potential contributions to trastuzumab resistance. Among them, KLK10 was verified to be a potential therapeutic target for reversing trastuzumab resistance. In summary, this study provides a new clue to screen molecular targets and predictive biomarkers for trastuzumab resistance.
['Wang|Zhuo|Z|', 'Ruan|Beihong|B|', 'Jin|Yi|Y|', 'Zhang|Yulong|Y|', 'Li|Jiaqiu|J|', 'Zhu|Liyuan|L|', 'Xu|Wenxia|W|', 'Feng|Lifeng|L|', 'Jin|Hongchuan|H|', 'Wang|Xian|X|']
D000074322:Antineoplastic Agents, Immunological D001943:Breast Neoplasms D045744:Cell Line, Tumor D019295:Computational Biology D030541:Databases, Genetic D004305:Dose-Response Relationship, Drug D055808:Drug Discovery D019008:Drug Resistance, Neoplasm D005260:Female D015972:Gene Expression Regulation, Neoplastic D006801:Humans D007610:Kallikreins D058990:Molecular Targeted Therapy D034622:RNA Interference D018719:Receptor, ErbB-2 D015398:Signal Transduction D013997:Time Factors D014162:Transfection D000068878:Trastuzumab
KLK10 trastuzumab resistance breast cancer HER2